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Backgroud: A key strategy for the study of the tumor microenvironment is to implant human tumor cells in an
immunodeficient rodent strain ubiquitously expressing a fluorescent marker. Here, a novel nude rat expressing a
green fluorescent protein (GFP) transgene was established and engrafted with primary human tumor tissue in order
to separate tumor from stromal cell populations for subsequent molecular analysis.
Methods: SD-TG (GFP) 2BalRrrc transgenic rats were crossed with HsdHan™: rnu/rnu Rowett nude rats to develop a
GFP expressing immunocompromised rat. PCR and flow cytometry were used to follow the GFP genotype and
phenotype in newborns. After three to four generations, animals were implanted with 4 T1 dsRed murine breast
cancer cells or primary human glioblastoma (GBM) biopsies to generate xenografts for subsequent separation by
fluorescence-activated cell sorting (FACS).
Results: Fluorecence microscopy and reverse transcription-PCR demonstrated that GFP, under the control of the
human ubiquitin C promoter, was stably maintained and expressed in diverse organs over several generations.
Immunophenotyping of blood samples by flow cytometry confirmed that the immunodeficient features of the parental
rat strain, HsdHan™: rnu/rnu, were retained in the GFP nude rat. Both the murine cell line and human GBM biopsies
engrafted, and stromal cell populations were isolated from dissociated xenografts by FACS to > 95% purity.
Conclusions: A GFP transgene was stably introduced into a nude rat background in which human and murine cancer
cells successfully engrafted. This animal strain provides a novel in vivo system for detailed cellular and molecular
characterization of tumor-stroma interactions.
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The development of a human tumor is a collaboration
between a mutated cell and its microenvironment. The
idea that tumor growth was in part dependent on
normal cell types originated over 100 years ago when
Stephen Paget proposed the “seed and soil” hypothesis
in 1889 [1]. Although his original studies addressed the
pattern of development of metastasis in human patients,
modern studies have revealed that a complex crosstalk
between stromal compartments and tumor cells exists at
any point during neoplastic progression [2-5].* Correspondence: Lixg@sdu.edu.cn; Jian.Wang@biomed.uib.no
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unless otherwise stated.Stroma itself evolves during cancer development. It is
composed of many different cell types, including cancer-
associated fibroblasts (CAFs), endothelial cells, and di-
verse immune cells, as well as extracellular matrix [5].
Tumor cell signalling, survival, proliferation, and even
response to chemotherapy are all affected by stroma, but
its complexity makes it difficult to attribute specific
functional properties to any individual cell type. There-
fore, the ability to separate stromal from tumor cells to
high purity is essential in order to study tumor-stroma
interactions.
One ingenious way to isolate stroma has been to implant
tumor cells into an immunodeficient rodent engineered to
ubiquitously express a fluorescent marker protein. In the
last decades, several green, red, or cyan fluorescent immu-
nodeficient mice models, including two from our grouphis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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biopsies successfully engrafted [8-12]. Although these
models have been elegantly used to investigate the impact
of stromal cell types on multiple aspects of tumor progres-
sion, the major disadvantage of xenograft models in mice
is tumor size. A substantial amount of material might be
required to perform, for example, both genomic and
proteomic analyses. The starting cell number is especially
important when xenografts are first dissociated into single
cell suspensions and subsequently sorted into different cell
populations by fluorescence-activated cell sorting (FACS)
[6,7]. In addition, any further division of a xenograft based
on the complexity of cell types present may require an
even greater number of total cells at the start.
CAFs have been recognized as having an important role
during the development of epithelial tumor types [13-15],
and fluorescent immunodeficient mice have been an im-
portant tool in the characterization of the interaction be-
tween CAFs and tumor cells. Stroma however, has been
not well described for human gliomas. Intracranial xeno-
grafts that develop from primary human glioblastomas
(GBM) in nude rats recapitulate major characteristics of
the disease, including angiogenesis and tumor invasion. In
some cases, the xenografts express a stable invasive pheno-
type independent of angiogenesis over many generations
in animals, and therefore, present a unique opportunity to
examine molecular differences in histologically distinct
stroma [16]. One of our major goals is to characterize
these differences in terms of cell type and molecular pro-
files to aid in our understanding of the development ofFigure 1 GFP genotyping and assessment of fluorescence expression
under a fluorescence dissecting microscope. (B) Confirmation of the GFP g
1050 bp (lane 3), whereas heterozygous rats exhibited bands at both 1050
amplified from non-GFP (wild type) rats. (C) GFP expression in different org
fold change compared to the organ with the lowest expression (heart). Stathese tumor types. Transgenic Green fluorescent protein
(GFP) rats, which are also available [17-21], are not immu-
nodeficient and thus, are limited in their ability to generate
xenograft tumors. As clinically relevant glioma models do
develop in immunodeficient nude rats, in order to more
effectively study tumor stroma in this model system, we
wanted to develop a transgenic nude rat strain ubiqui-
tously expressing GFP. Human GBM biopsies as well as a
murine epitheial cancer cell line were implanted in GFP
nude rats to generate xenograft tumors. Highly enriched
stromal cell populations were isolated from the different
tumor types based on fluorescence.
Results
Generation of a GFP-expressing nude rat
In order to obtain a nude rat expressing GFP, the SD-TG
(GFP) 2BalRrrc transgenic rats were crossbred with
HsdHan™: rnu/rnu Rowett nude rats. Newborn rats were
genotyped at each generation for the presence of the
GFP transgene by PCR of genomic DNA isolated from
rat tails (Figure 1B). After each cross, heterozygous GFP
rats and parental HsdHan™: rnu/rnu Rowett nude rats
were again crossbred to obtain heterozygous GFP nude
rats and used for tumor implantation experiments after
the third generation.
GFP nude rats stably express GFP in diverse organs
Evaluation of GFP expression was peformed in two ways.
Firstly, fresh internal organs harvested from a heterozy-
gous GFP nude rat were examined grossly under a UVin GFP nude rats. (A) Organs from GFP positive animals visualized
enotype by PCR. Homozygous GFP rats displayed a single band at
and 799 bp (lanes 2, 7, and 11). Only a single band at 799 bp was
ans as estimated by quantitative RT-PCR and expressed as a relative
ndard error bars are indicated on the columns.
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ney, intestine, lung, and liver were all highly fluorescent
indicating robust GFP expression (Figure 1A). Secondly,
RT-PCR was used to detect and quantify GFP expression
at the mRNA level (Figure 1C). RT-PCR revealed that all
organs expressed GFP at the transcriptional level. How-
ever, the expression levels differed based on tissue type;
GFP was expressed at the highest levels in brain and the
lowest in the heart relative to GAPDH.
GFP nude rats exhibit the same immunophenotyping as
nude rats
The purpose of the cross was to integrate the GFP
transgene into an immunodeficient rat background. ToFigure 2 Immunophenotyping of GFP rat and parental strains by flow
immunocompetent rat. Left panels display the distribution of B cells (PE co
panels display the distribution of NK cells (Alexa 647 conjugated CD161).determine whether the homozygous GFP animals re-
tained the immunodeficient features of the parent nude
rat strain (HsdHan™: rnu/rnu Rowett nude rat), per-
ipheral blood was collected from GFP nude rats and
the two parental rat strains (SD-TG (GFP) 2BalRrrc
transgenic and HsdHan™: rnu/rnu Rowett nude rats).
White blood cells were isolated, incubated with dif-
ferent fluorescently conjugated antibodies specific for
various immune cells types (T, B, and NK cells), and
analyzed by flow cytometry. Both the GFP nude rats
and HsdHan™:rnu/rnu Rowett nude rats lacked T
cells (CD3) but retained B cells and NK cells (CD19
and CD161, respectively; Figure 2). These results in-
dicated that the immune cell profile of the parentalcytometry. (A) GFP nude rat; (B) nude rat; and (C)
njugated CD19) and CD3 positive T cells (APC conjugated CD3). Right
Table 1 GBM Tumor take rate in the GFP nude rats
Patients Take rate
P1 0/2 (0%)
P2 3/3 (100%)
P3 2/2 (100%)
P4 2/2 (100%)
P5 3/3 (100%)
P6 3/3 (100%)
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crossbred nude rats.
Murine breast and human GBM cell populations engraft
in GFP nude rats
One of the most important features for xenograft models
is that the host animal does not reject tissue from an-
other species. To determine whether the GFP nude rat
provided a favorable environment for engraftment from
other species, murine as well as human tumor cells were
implanted. Orthotopic implantations were performed at
two different locations, in the mammary fat pad and
within the brain. For an epithelial tumor type, the mur-
ine breast cancer cell line 4 T1 transfected with dsRed
was injected into the mammary fat pad. Tumor take was
100% at this site for 4 T1 cells, and tumors had reached
2 cm in size within 21 days.
To examine the development of gliomas in the rat brain,
spheroids derived from six primary GBMs were trans-
planted intracranially into GFP nude rats. Animals were
monitored by MRI once each week, following implant-
ation, for tumor progression (Figure 3A, B). Tumors de-
veloped in rats for 5/6 different GBMs within 6 weeks
(Table 1). All animals (n = 13) for these five cases (P2-P6)
developed tumors whereas no animal (n = 2) developed a
tumor from a single case (P1) within this timeframe. An
MRI scan of a typical GBM xenograft revealed a highly ag-
gressive tumor that was invading the contralateral hemi-
sphere of the GFP nude rat. The lateral ventricle was also
obstructed, and the tumor was growing out of the skull
(Figure 3A, B). H&E staining of the tumor revealed a
somewhat circumscribed lesion with local infiltration into
the surrounding normal brain tissue (Figure 3C).
High purity separation of stromal cells from tumors by FACS
The models used allowed separation efficiency to be
tested when both tumor and stromal cells were fluores-
cently labeled or when only stromal cells were labeled.
Enzymatic dissociation of dsRed 4 T1 breast cancer xe-
nografts from GFP nude rats (Figure 4A) generated
mixed single cell suspensions as demonstrated by the
presence of both red (80%-90%) and green fluorescentFigure 3 Engraftment of GBM biopsy in the GFP nude rat. (A) MRI sca
(B) MRI scan T2 sequences reveal hydrocephalus of the animal brain. (C) Hcells (10%-20%) (Figure 4B). When sorted based on
fluorescence, the resultant cell populations displayed
high purity (>95%; Figure 4C, D).
To determine whether tumor and stromal cells could be
efficiently separated based on a single fluorescent marker,
fresh GBM xenografts from the GFP nude rats were enzy-
matically dissociated into a single cell suspension. Isolated
cell populations were obtained based on GFP with high
speed FACS (Figure 5A). In order to determine purity,
ICC was subsequently performed on sorted cell popula-
tions with an antibody specific for the human nucleus.
ICC revealed that isolated cell populations were well
separated into human (red nuclei) and rat cell types
(DAPI; >95%; Figure 5B,C). The sorted cells were quanti-
fied, and the total number for cells in each compartment
was compared to experiments performed with xenografts
from GFP NOD/SCID mice (Table 2). In xenografts from
the GFP nude rat, the total number of GFP+ sorted stro-
mal cells (> 106) was approximately 10 times greater than
in xenografts from GFP NOD/SCID mice. GFPneg human
tumor cells comprise 80% of the xenograft in both rats
and mice. The total number of GFPneg cells sorted was ap-
proximately 5.0×106 and 1.0×106 from xenografts of GFP
nude rats and GFP NOD/SCID mice, respectively. These
results indicated that increased numbers of cells were rou-
tinely sorted from individual xenografts in rats based on
fluorescence.
Discussion
Transgene technology allows researchers to introduce a
wide range of fluorochrome genes into cells/organisms
so that they can be visualized with the desiredn T1 with contrast enhancement (gadolinium contrast reagent).
&E staining of the corresponding tumor.
Figure 4 dsRed 4 T1 xenograft in GFP nude rat. (A) Subcutaneous 4 T1 dsRed tumor in situ after removing the skin flap of the GFP nude
rat (20× magnification). (B) Cell suspension of a dissociated 4 T1 tumor displays a mixture of individual GFP expessing host cells with dsRed
transfected tumor cells (20× magnification). High purity separation of (C) GFP expressing stromal cells (green) and (D) dsRed expressing 4 T1
tumor cells (red) after FACS sorting.
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antly, while they are still living. Immunodeficient animals,
such as nude mice, nude rats as well as SCID mice have
been extensively used in cancer research because they en-
able xenografting of human cancer cells or biopsies, and
thus generate models that more closely resemble the hu-
man tumor phenotype. Together, the two strategies pro-
duce powerful experimental tools to characterize the
relationship between tumor and microenvironment. In
order to begin to define the stroma for human GBM, we
established a novel GFP nude rat strain by cross breeding
immunocompetent GFP transgenic rats with immunodefi-
cient nude rats. GFP was expressed in all organs examined
although mRNA expression levels was dependent on the
tissue type. GFP nude rats expressed the immune defi-
ciencies of the parent nude rat, and thus, 4 T1 breast
cancer cells as well as human GBM biopies engrafted. Fi-
nally, fluorescent stromal cells were separated from non-
fluorescent or dsRed cancer cells to high purity by FACS.
In recent years, numerous fluorescent animals, such
as mouse, rat, pig, and rabbit, have been established
[8,17,22,23]. GFP transgenic rats were first introduced as
a model to study organ transplantation in 2001 [17], as
well as physiological aspects of a specific cell population
or organ [20,24-27]. Athymic nude rats were firstreported in the 1970s [28]. Since then, a plethora of ex-
periments exploiting cancer xenografts in nude rats has
been reported. The focus of our current experiments is
glioma stroma, but fluorescent transgenes have been ele-
gantly used to elaborate the evolution of stroma during
tumor progression. Red fluorescent protein (RFP) positive
human prostate cancer, colon cancer, breast cancer and
fibrosarcoma cells have been implanted orthotopically
into GFP nude mice so that tumor-host interactions could
be visualized by dual-color imaging [10]. In addition, the
origin of some stromal cells from the bone-marrow has
been illuminated through experiments where tumor was
implanted into non-transgenic SCID mice which received
bone marrow transplants from GFP SCID mice [29]. Fi-
nally, multiple color proteins have been used to investi-
gate tumor-stroma interactions in real time. Imaging was
performed on live animals where cyan fluorescent protein
(CFP) expressing nude mice were implanted with dual-
colored human pancreatic cancer cells expressing RFP in
the cytoplasm and GFP in the nucleus [11].
Even within our group, we have previously established
a GFP NOD/SCID mouse strain to investigate tumor-
host interactions. Orthotopic implantation of both U87
dsRed GBM and 4 T1 dsRed breast cancer cell lines gen-
erated tumors in GFP NOD/SCID mice, and stromal
Figure 5 FACS sorting of cell populations from a GBM xenograft in the GFP nude rat. (A) Dot plot displays distinction of two cell
populations, the GFP negative tumor population (GFPneg) and the GFP positive stromal population (GFP+), based on X-axis FITC fluorescence
distribution. Cell populations were stained with a pan-human specific marker for human nuclear factor (HuNu) before (B) and after (C) sorting.
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ever, homozygosity of the GFP transgene is a lethal geno-
type on a NOD/SCID background. Breeding is a
cumbersome process as animals must be genotyped at
each generation, and only heterozygous pairs used. Ultim-
ately sufficient numbers of GFP NOD/SCID mice are slow
to generate. A dsRed NOD/SCID mouse strain was also
established as the fluorchrome also has favorable spectral
properties at high-emission wavelengths. Homozygosity of
the dsRed transgene in NOD/SCID mice is not detrimen-
tal to animals as they are completely viable and fertile [7].
For this reason, the dsRed NOD/SCID mice allow for easy
breeding and maintenance of the colony.
The GFP nude rat though has several experimental ad-
vantages over fluorescent NOD/SCID mice. Firstly, when
maintained under specific pathogen-free conditions, theTable 2 Quantification of dissociated/sorted cells from a gliobla
Cell compartment GFP nude rats
R1 R2
Total number of cells 1.3×108 1.4×108
GFP+ stromal cells 1.0×106 1.3×106
GFPneg tumor cells 5.0×106 5.0×106GFP nude rats have a maximum life span of 1.5 to
2 years or more [31] whereas NOD/SCID mice have a
life span of 1 year (JAX notes). This lengthy life span of
the nude rat provides sufficient time in some instances
for studies regarding cancer development of more slow
growing tumor types as well as to obtain survival data.
In addition, NOD/SCID mice are predisposed to thymic
lymphoma as well as wasting and infections which do
not occur as frequently in nude rats so that more ani-
mals reach experimental endpoints. Secondly, since the
immunological characteristics of the GFP nude rat are
the same as the nude rat, the absence of T lymphocytes
but the retention of B cell linages, the GFP nude rats
can be used to study host resistance to experimental in-
fection [31]. Finally, the size of the nude rat facilitates
many aspects of in vivo experiments simply becausestoma xenograft in GFP nude rats and GFP NOD/SCID mice
GFP NOD/SCID mice
R3 M1 M2 M3
1.7×108 1.1×107 1.0×107 1.3×107
1.5×106 2.0×105 2.0×105 2.5×105
5.0×106 1.0×106 1.0×106 1.0×106
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timately more feasible to isolate sufficient numbers of
diverse cell types for molecular analyses from tumors
grown in GFP nude rats. Furthermore, rats are simply
much more convenient to use, particularly for intra-
cranial surgeries, such as xenotransplantation of GBM
(J. Wang, personal observation), and they are less sensi-
tive to overdosing with anesthesia.
Conclusions
The GFP transgene has been successfully bred onto a
nude rat background. Murine and human cancer cells
were engrafted in these animals at a high tumor take
rate, and the resulting tumors could be separated into
stromal and tumor cell compartments to high purity on
the basis of fluorescence. Nude rats ubiquitously ex-
pressing fluorescent markers are a unique tool for
characterization of tumor stroma from diverse human
cancers.
Materials and methods
Ethics statement
The collection of tumor tissue from patients was ap-
proved by the Regional Ethics Committee at Haukeland
University Hospital (Project number 013.09; Bergen,
Norway). All patients signed informed written consent.
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health.
The protocol was approved by the Committee on the
Ethics of Animal Experiments of the University of
Bergen (Permit Number: 20135415).
Cell culture
The murine breast cancer cell line 4 T1 (American Type
Culture Collection, ATCC CRL-2539; Rockville, MD, USA)
was transfected with a dsRed-expressing lentiviral vector
(Discosoma sp. red fluorescent protein) [30]. Cells were cul-
tured in RPMI-1640 medium (Bio-Whit-taker; Verviers,
Belgium) containing fetal bovine serum (FBS;10%),
Penicillin/Streptomycin (100 units/mL), non-essential
amino acids (3.2%), plasmocin (0.005 mg/mL; InvitroGen;
San Diego, CA, USA), and L-glutamine (400 mol/L;
Lonza; Cologne, Germany), and were maintained in a hu-
midified environment at 5% CO2 and 37°C.
Tumor spheroid culture
Six human brain tumor biopsies (GBM) were obtained
from the Department of Neurosurgery, Haukeland
University Hospital (Bergen, Norway). Spheroids were pre-
pared and selected for intracerebral implantation as previ-
ously described [32]. Briefly, surgical samples were minced
into 0.5 mm fragments and cultured in agar-coated tissue
culture flasks in DMEM containing FBS (10%). Spheroidswere maintained in a humidified environment at 5% CO2
and 37°C, and the medium was changed once per week.
After 2 weeks, ten spheroids with diameters between 200
and 300 μm were selected for intracerebral implantation
into rats.
Animals
SD-TG (GFP) 2BalRrrc transgenic rats (stock no. 0065,
Rat Resource & Research Center, University of Missouri;
Columbia, MO, USA) harboring the GFP transgene
under transcriptional control of the human ubiquitin-C
promoter with a woodchuck hepatitis virus posttran-
scriptional regulatory element (WRE) were crossed with
HsdHan™: rnu/rnu Rowett nude rats (stock no. 20196,
Harlan Laboratories; Horst, Netherlands) to make first
generation GFP heterozygous animals [33]. Inbreeding
was subsequently performed between heterozygous GFP
rats and the parent HsdHan™: rnu/rnu Rowett nude
strain in order to obtain heterozygous GFP nude rats.
Experimental animals could be used at the third or
fourth generation after confirmation of genotype by
PCR.
DNA extraction and GFP genotyping by PCR
Genomic DNA was extracted from freshly harvested tissue
from rat tails according to the manufacturer’s protocols
(Extract-N-Amp Tissue PCR Kit; Sigma; St. Louis, MO,
USA). A master mix was made which contained Extract-
N-Amp PCR Reaction Mix (10 μL), primers 1, 2, and 3
(0.3 μL of each at 25 μM), and sterile water (5.1 μL).
Master mix (16 μL) and DNA template (25 ng in 4 μL)
were added together for a final reaction volume of 20 μL.
Cycling parameters used were the following: 1 cycle 94°C
3 min; 35 cycles 94°C 30 s, 60°C 30 s, and 72°C 75 s; 72°C
for 10 min. PCR products were analyzed on a 3% agarose
gel in Tris-acetate, EDTA buffer. The wild type fragment
migrated at approximately 799 bp, and the transgenic
fragment at 1050 bp. Primers used for GFP genotyping of
DNA were: R52 int 1 F: 5′-AGCAATGAATAGCC
TCTCTCCT-3′, R52 int 1R: 5′-CCCATATGTGCCAAGC
ACTTTACC-3′, U3R-0: 5′-GTCTGAAGGGATGGTTG
TAGCTGT-3′.
Quantitative Real Time PCR of GFP expression
Diverse tissues from GPF nude and nude rats were har-
vested and immersed in RNA later solution (Ambion;
Austin, TX, USA). Tissue was finely chopped and passed
through a 23G needle five times for homogenization. RNA
extraction was performed with the RNeasy Plus Mini kit
(Qiagen; Hilden, Germany), according to the manufac-
turer’s protocols. RNA was quantified on the Nanodrop
ND-1000 instrument (NanoDrop products; Wilmington,
DE, USA). cDNA was synthesized with the iScript Select
cDNA synthesis kit (Bio-Rad; Hercules, USA) according
Yang et al. Cancer Cell International  (2014) 14:541 Page 8 of 9to the manufacturer’s protocols. Quantitative real time
PCR was performed on cDNA in iQ™ SYBR Green super-
mix (1×; Bio-Rad, Hercules, CA, USA). cDNAs were amp-
lified in a Bio-Rad iCycler 96 well instrument (Bio-Rad),
and reactions for GFP and GAPDH were run in triplicate.
Cycling parameters used were: 1 cycle 95°C 5 min; 40 -
cycles 95°C 30 s, 60°C 40 s, and 72°C 20 s; 1 cycle 72°C
1 min; and 1 cycle 55°C 30 s. The following primers were
used to amplify GFP and glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH): GFP forward primer: 5′-ACG
TAAACGGCCACAAGTTC-3′; GFP reverse primer: 5′-
AAGTCGTGCTGCTTCATGTG-3′; GAPDH forward
primer: 5′-TGTGCAGTGCCAGCCTCGTC-3′, GAPDH
reverse primer: 5′-TGCCACTGCAAATGGCAGCC-3′.Immunophenotyping
Peripheral blood was collected from the tails of the
GFP-nude, and the parent nude and immunocompetent
rats. Blood samples were treated with Easylyse buffer to
lyse red blood cells (S2364, DAKO; Oslo, Norway), and
the remaining cell types were pelleted and resuspended
in staining buffer (2% FBS in PBS). Cell suspensions
were incubated for 30 min at room temperature with
fluorescently conjugated antibodies against rat CD3
(eBioscience; San Diego, CA, USA), CD4, CD8, CD19
(Biolegend; San Diego, CA, USA), and isotype control.
Analyses were performed on the FACS Aria II (BD Bio-
sciences; Erembodegem, Belgium).In vivo experiments
For implantation of breast tumor cells, dsRed-expressing
4 T1 cells were detached from monolayer with trypsin
(Lonza, Cologne, Germany) and diluted in PBS. The con-
centration of 4 T1 cells was adjusted to 1×107 cells/mL.
Rats were anesthetized with isofluran (Abbott; Oslo,
Norway), and 1×106 cells were injected into the mammary
fat pad. Tumor size was measured every two days by cali-
per. When the diameter of tumors reached 2 cm, rats were
sacrificed, and tumors were collected.
Stereotactic intracranial implantations for GBM were
performed as previously described [16]. Briefly, rats were
anesthetized with a mixture of 10 ml Fentanyl (50 mg/mL;
Hameln, Germany) and 1 mL Domitor (1 mg/mL; Orion
Pharma, Finland). Rats were fixed in a stereotactic frame
(Narishige Group; Tokyo, Japan), a small hole was drilled
in the skull, and ten tumor spheroids were slowly injected
through a wide bore Hamilton syringe (Hamilton; Reno,
NV, USA) into the right frontal cortex. Rats were sacri-
ficed when symptoms developed, and brains were re-
moved. Primary GBM transplants were carefully dissected
out from affected brains, and new biopsy spheroids
were generated. Spheroids were then seeded on a plastic
surface and examined ex vivo using a fluorescencemicroscope (Leica DMI 6000B, Leica Microsystems;
Wetzlar, Germany).
Fluorescence microscopy
Fresh organs were visualized under a fluorescence dis-
secting microscope (Model C-DSD230; Nikon, Japan)
with a UV-filter.
MRI scanning
MRI scanning was performed on anesthetized animals
(1.5% isofluoran mixed with 50% air and 50% O2) in a
Bruker Pharmascan 7 T MR scanner (Bruker Biospin
MRI GmbH; Ettlingen, Germany). An axial T1 weighted
MSME sequence (TR 1000 ms, TE 8.7 ms, slice thick-
ness 1 mm, FOV 3.5 cm, matrix size 256 × 256, 20 slices)
was acquired before and after administration of subcuta-
neous injection of contrast agent (1.0 mL of 0.5 mmol/mL
Omniscan; Nycomed Amersham, Oslo, Norway). An axial
T2 weighted RARE sequence was also acquired (TR
4200 ms, TE 36 ms, slice thickness 1 mm, FOV 3.5 cm,
and matrix size 256 × 256, 20 slices).
Fluorescence-activated cell sorting
4 T1 breast tumors were dissociated into single cell sus-
pensions as previously described [30]. For GBM xeno-
grafts, fresh tissue was finely minced and dissociated into
a single cell suspension with the Neural Tissue Dissoci-
ation kit (Miltenyi Biotec; Bergisch Gladbach, Germany)
according to the manufacturer’s protocols. The mixed cell
suspensions were subsequently sorted into isolated tumor
and stromal cell populations with the FACS Aria II
(Becton Dickinson; Erembodegem, Belgium).
Histological analysis and immunostaining
Rat brains were fixed in 4% formaldehyde immediately fol-
lowing sacrifice. Tissues were embedded in paraffin, and
5 μm sections were prepared and stained with Hematoxylin
and eosin (H&E) for histological analysis.
Immunocytochemistry (ICC) was performed on isolated
cell populations following FACS. Mouse anti-HuNu (1:100,
Millipore, MA, USA) and TXRD-conjugated goat anti-
mouse (1:100; Southern Biotech; AL, USA) were used to
distinguish human tumor cells from rat host cells. Cells
were then mounted in Vectashield mounting medium
with DAPI for identification of all nuclei present (Vector
Laboratories; Burlingame, CA, USA). Immunocytochem-
istry was visualized under confocal microscopy (Leica TCS
SP5; Leica Microsystems Wetzlar, Germany).
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